Risk factors
Kairos Pharma (KAPA) risk factors
Item 1A of every Kairos Pharma, Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors93 risks2 new1 dropped2 reworded
New risks focus on rapid U.S. policy changes, including taxation and healthcare, and reduced access to debt and equity capital.
Filed Mar 31, 2026 - FY2024 10-K risk factors92 risks
Kairos Pharma faces extensive risks typical of early-stage biotechnology firms, dominated by severe funding needs, single-source manufacturing dependencies, and heavy reliance on key management.
Filed Apr 15, 2025